Regcell Inc. has raised $66 million in new financing and Japanese government support to move its Nobel-linked regulatory T-cell (Treg) platform toward the clinic, advancing an epigenetic reprogramming approach designed to convert disease-driving immune cells into antigen-specific Tregs.
